Table 1.
Characteristics of 18 adults undergoing therapy with clofarabine followed by cyclophosphamide
| Characteristics | |
|---|---|
| Male/female, no. | 8/10 |
| Median age, y (range) | 51 (27-67) |
| Disease type/status | |
| AML, no. patients | 12 |
| Relapse short CR1, less than 6 mo | 2 |
| Refractory (primary/multiple) | 10 (8/2) |
| ALL, no. patients | 6 |
| Relapsed T-ALL | 1 |
| Relapsed Ph+ ALL | 1 |
| Pre-B-ALL (relapsed on therapy/refractory) | 4 (1/3) |
| Biologic features (range) | |
| Pretreatment peripheral blasts, ×109/L | |
| AML | 10.3 (0.6-52) |
| ALL | 21 (14.1-51) |
| Secondary AML, no./total no. of patients | 7/12 |
| MDS/AML | 5 |
| Treatment-related AML | 2 |
| Adverse cytogenetics, no./total no. of patients | 14/18 |
| AML | 10/12* |
| ALL | 4/6† |
| Prior therapy, no. patients | |
| Stem-cell transplantation | 3 |
| Allogeneic | 2 (1 AML, 1 ALL) |
| Autologous | 1 (ALL) |
| Induction regimens, no./total no. | |
| 2 or more | 13/18 (9 AML, 4 ALL) |
| 3 or more | 7/18 (4 AML, 3 ALL) |
Data are numbers unless otherwise stated.
*
Seven complex (≥ 5 abnormalities), 2 monosomy 7 (+/- inv 3), 1 trisomy 21.
†
Three complex (≥ 5 abnormalities, including 6q- and trisomy 8), 1 Ph+.